<DOC>
	<DOCNO>NCT02671708</DOCNO>
	<brief_summary>Autologous hematopoietic stem cell transplantation ( Auto-HSCT ) effective alternative allogeneic HSCT low-risk intermediate-risk acute myeloid leukemia ( AML ) without HLA-matched donor . At present , best condition regimen AML undergo auto-HSCT remains discussion . In study , safety efficacy IDA+BUCY BUCY myeloablative conditioning regimens low-risk intermediate-risk AML undergo auto-HSCT evaluate .</brief_summary>
	<brief_title>IDA+BUCY v BUCY Conditioning Regimen Low-risk Intermediate-risk AML Undergoing Auto-HSCT</brief_title>
	<detailed_description>Auto-HSCT effective alternative allogeneic HSCT low-risk intermediate-risk AML without HLA-matched donor . BUCY condition regimen standard myeloablative regimen AML undergoing auto-HSCT . However , auto-HSCT appear high relapse rate lower transplant-related mortality , compare allo-HSCT . To reduce relapse rate , IDA add condition regimen . In study , safety efficacy IDA+BUCY BUCY myeloablative conditioning regimens low-risk intermediate-risk AML patient undergo auto-HSCT evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Lowrisk intermediaterisk AML Achieving CR one cycle induction , receive three cycle consolidation therapy include moderate high dos Arac combine regimen With negative MRD mobilization collect peripheral blood stem cell Without HLAmatched donor ( relate unrelated ) Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>